Empallo Receives Second U.S. Patent, Expanding Its AI Work in Cardiovascular Care


EMPALLO — Nov. 16, 2026: Empallo, Inc., a healthcare technology company, has been issued its second U.S. patent: No. 12,763,209, granted Oct. 13, 2026 by the U.S. Patent and Trademark Office (USPTO). The patented methods use AI to estimate how patients with cardiovascular, metabolic and renal conditions could respond to treatment, which may help clinicians consider changes in care sooner. Heart failure is a major focus of this work and is the example used throughout this article.
The challenge of delayed clinical feedback, especially in heart failure
Cardiovascular, metabolic and renal conditions frequently occur together, and the patented methods are designed to apply across all three. Heart failure is a particularly clear example of the problem the technology addresses.
Heart failure is one of the leading causes of hospitalization in older adults, and patients with the same diagnosis can follow markedly different clinical trajectories. Some respond to therapy and stabilize quickly. Others stall or deteriorate, and the early signs are often subtle. Clinicians typically adjust therapy and then monitor weight, laboratory values and vital signs over several days to determine whether treatment is working, which can delay needed changes in care.
Empallo’s newly patented technology is designed to shorten that interval. It applies machine learning to routinely collected clinical data and analyzes how those measurements change over time to estimate a patient’s likely trajectory.
Supporting key clinical decisions
The methods are designed to give clinicians additional information to consider as they make decisions throughout the care of patients with cardiovascular, metabolic or renal conditions, including heart failure. Clinical judgment stays with the treating clinician.
Cardiac condition assessment. Estimates how a patient’s disease is likely to progress, in conditions including cardiac amyloidosis (ATTR-CM) and heart failure.
Discharge and follow-up planning. Highlights patients who may be at higher risk of readmission or other adverse events, informing discharge timing and level of support.
Treatment response. Anticipates how a patient may respond to a therapy, such as a diuretic, informing whether an adjustment may be warranted.
The system also identifies which clinical inputs most influenced a given assessment, such as natriuretic peptide levels or creatinine, so clinicians can see the basis for a prediction and not only a score.
A complementary foundation in medical imaging
Empallo’s first patent, U.S. Patent No. 12,243,636, “Apparatus and Method for Diagnosing a Medical Condition From a Medical Image,” issued March 4, 2025, addresses a different clinical question: what a medical image shows. Its lead example is the chest X-ray, one of the most common studies ordered for patients with suspected heart failure.
The technology is trained on radiographs paired with the radiology reports written about them, so the software learns to connect what radiologists see with how they describe it. Once trained, it can grade the severity of pulmonary edema, the buildup of fluid in the lungs that is common in heart failure and central to fluid management, from the image alone. It can also generate a written explanation of its findings, giving clinicians visibility into the basis for an assessment. The approach is described for other imaging types as well, including MRI, nuclear medicine imaging and ultrasound.
Where the first invention interprets a patient’s imaging, the second anticipates how that patient’s condition is likely to progress and respond to treatment. Both are AI tools that could be layered on top of electronic health record (EHR) platforms. Empallo has built its own EHR on modern infrastructure, which supports data interoperability and the deployment of tools, including AI, across the care delivered through its affiliated medical groups.
“These patents protect valuable innovation, and we’re just as excited about the EHR we’ve built, which makes it easy to deploy and use helpful tools, including AI. Its FHIR-native foundation lets us build features ourselves or plug in third-party solutions. That flexibility is uncommon in healthcare, and it helps clinicians save time on admin work and improve accuracy,” said Claire Beskin, CEO of Empallo.
Patent details
U.S. Patent No. 12,243,636 B2: Apparatus and Method for Diagnosing a Medical Condition From a Medical Image. Issued March 4, 2025. Pairs medical images with their written reports to train AI that grades the severity of a condition, such as pulmonary edema on chest X-rays, and explains its findings in writing.
U.S. Patent No. 12,763,209 B2: Methods and Systems for Determining Assessments of Cardiovascular, Metabolic, and Renal Syndromes, Diseases, and Disorders. Issued October 13, 2026. Applies machine learning to patient data over time to forecast treatment response and risk across heart, kidney and metabolic conditions.
Empallo worked on both patents with Katherine Rubino, who is currently a Partner at Wiggin and Dana LLP. Katherine holds a J.D. from Suffolk University Law School and a PharmD from Northeastern University, and is an active member of the Boston and Cambridge innovation community.
Note: The patents protect the methods and systems described in their claims. They don't, by themselves, indicate that a product is commercially available or has received FDA clearance or approval.
About Empallo
Empallo is a healthcare technology company that develops a proprietary electronic health record (EHR) platform and supports affiliated medical groups delivering cardiac care.